Clinical trial · no report yet · Phase 3
Krascendo 2
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- NCT06793215 ↗
- Recruiting
- Hoffmann-La Roche
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 6 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Patients With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Non-Small Cell Lung Cancer; KRAS G12C Lung Cancer
- Interventions
- Divarasib; Pembrolizumab; Pemetrexed; Carboplatin; Cisplatin
- Arms
- Divarasib + Pembrolizumab · Experimental
- Pembrolizumab + Pemetrexed + Carboplatin or Cisplatin · Active comparator
- Enrollment
- 600 (estimated)
- Primary outcomes
- Progression-Free Survival (PFS)
- Overall Survival (OS)
- Sponsor
- Hoffmann-La Roche with Chugai Pharmaceutical
- Start
- Oct 24, 2025
- Primary completion
- Nov 30, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06793215 · updated Oct 6, 2026